Vol. 6, Issue 1, Part A (2024)

Severe mitral stenosis poses a significant health burden globally, necessitating effective therapeutic interventions. Percutaneous transvenous mitral commissurotomy (PTMC) has emerged as a promising minimally invasive procedure for managing severe mitral stenosis. When the apparatus becomes involved in rheumatic disease, it blocks the primary inflow from the left atrium to the left ventricle, a condition known as mitral stenosis. A mix of stenosis and regurgitation is observed in patients with mitral valve disease. Increased pressure causes disease or mortality in multiple patients, even after percutaneous therapy. In order to determine whether pulmonary hypertension can be alleviated in individuals suffering from severe mitral stenosis by the use of percutaneous transvenous mitral commissurotomy. This research paper aims to evaluate the efficacy, safety, and clinical outcomes associated with PTMC in patients with severe mitral stenosis.